Leap Therapeutic Financials
This page shows Leap Therapeutic (LPTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not operating cash generation, is the engine here, while research spend remains the main controllable cost.
In FY2025, reported profit detached from operating reality: net income turned positive at$5.0M even as operating loss remained-$41.1M and operating cash flow stayed-$43.9M . Paired with$107.6M of financing inflow and shares outstanding rising to 83.9M, the cleaner earnings line looks like a recapitalization year rather than a business that began funding itself.
The cost base is research-led rather than commercial-led: R&D fell from
The balance sheet is lightly levered, with total liabilities of just
Financial Health Signals
Leap Therapeutic does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Leap Therapeutic passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
For every $1 of reported earnings, Leap Therapeutic used $8.78 of operating cash (-$43.9M OCF vs $5.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Leap Therapeutic reported an operating loss of $41.1M against $24K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Leap Therapeutic's EBITDA was -$41.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 41.4% from the prior year.
Leap Therapeutic reported $5.0M in net income in fiscal year 2025. This represents an increase of 107.4% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Leap Therapeutic held $14.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Leap Therapeutic's ROE was 3.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 197.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Leap Therapeutic invested $25.7M in research and development in fiscal year 2025. This represents a decrease of 55.1% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
LPTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | $1.5M0.0% | $1.5M | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $25.7M-55.1% | $57.2M-21.9% | $73.2M+62.9% | $45.0M+39.8% | $32.2M+57.5% | $20.4M-16.2% | $24.4M+11.6% | $21.8M-3.0% | $22.5M-3.4% | $23.3M |
| SG&A Expenses | N/A | $10.9M-15.4% | $12.8M-7.0% | $13.8M+17.0% | $11.8M+9.6% | $10.8M+12.0% | $9.6M+5.8% | $9.1M+1.8% | $8.9M-9.4% | $9.8M+145.5% | $4.0M |
| Operating Income | N/A | -$41.1M+41.4% | -$70.1M+19.5% | -$87.0M-53.3% | -$56.8M-37.0% | -$41.4M-45.2% | -$28.5M+14.7% | -$33.5M-8.8% | -$30.8M+4.9% | -$32.4M-18.5% | -$27.3M |
| Interest Expense | N/A | $24K | N/A | N/A | $54K+31.7% | $41K+5.1% | $39K+69.6% | $23K+21.1% | $19K-96.4% | $528K | N/A |
| Income Tax | N/A | $5.3M+798.3% | $585K | N/A | $147K+712.5% | -$24K-1100.0% | -$2K+33.3% | -$3K-115.0% | $20K+112.7% | -$157K | N/A |
| Net Income | N/A | $5.0M+107.4% | -$68.0M+16.0% | -$81.0M-48.4% | -$54.6M-34.5% | -$40.6M-47.5% | -$27.5M+16.4% | -$32.9M-42.2% | -$23.1M+22.2% | -$29.7M-16.0% | -$25.6M |
| EPS (Diluted) | — | $0.07 | -$1.81 | -$3.98 | -$4.82 | -$0.47 | -$0.63 | -$1.47 | -$2.11+36.3% | -$3.31 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
LPTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $163.2M+232.2% | $49.1M-32.5% | $72.8M+3.5% | $70.4M-40.3% | $117.9M+116.9% | $54.4M+630.0% | $7.4M-61.0% | $19.1M-34.4% | $29.1M+350.1% | $6.5M |
| Current Assets | $162.1M+237.4% | $48.0M-32.9% | $71.6M+5.4% | $68.0M-41.9% | $116.9M+123.6% | $52.3M+1132.6% | $4.2M-75.5% | $17.3M-37.4% | $27.7M+586.5% | $4.0M |
| Cash & Equivalents | $14.0M-70.3% | $47.2M-33.1% | $70.6M+7.9% | $65.5M-43.0% | $114.9M+120.7% | $52.1M+1238.2% | $3.9M-76.1% | $16.3M-36.7% | $25.7M+3145.5% | $793K |
| Total Liabilities | $9.7M-31.3% | $14.1M+11.0% | $12.7M+10.4% | $11.5M+14.6% | $10.0M+29.8% | $7.7M-16.1% | $9.2M-7.1% | $9.9M-44.8% | $17.9M-83.2% | $106.7M |
| Current Liabilities | $4.6M-67.6% | $14.1M+11.0% | $12.7M+13.0% | $11.2M+12.4% | $10.0M+35.5% | $7.4M-13.1% | $8.5M+31.5% | $6.5M+6.0% | $6.1M-83.2% | $36.2M |
| Total Equity | $153.5M+338.0% | $35.0M-41.7% | $60.1M+2.2% | $58.9M-45.4% | $107.9M+131.3% | $46.7M+2767.3% | -$1.7M-119.1% | $9.2M-17.5% | $11.1M+111.1% | -$100.2M |
| Retained Earnings | -$462.5M+1.0% | -$467.4M-17.0% | -$399.6M-25.6% | -$318.2M-20.7% | -$263.6M-18.2% | -$223.0M-14.3% | -$195.2M-27.1% | -$153.5M-17.7% | -$130.4M-29.5% | -$100.7M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
LPTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$32.9M | -$43.9M+27.2% | -$60.3M-37.8% | -$43.8M+10.8% | -$49.0M-39.5% | -$35.2M-35.4% | -$26.0M+3.5% | -$26.9M-3.3% | -$26.0M-17.6% | -$22.1M+12.6% | -$25.3M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $100K | N/A | $64K-55.6% | $144K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$27.0M | N/A | -$22.2M+12.9% | -$25.5M |
| Investing Cash Flow | N/A | -$97.0M | N/A | $49.0M | N/A | N/A | $25K+129.4% | -$85K | N/A | -$64K+55.6% | -$144K |
| Financing Cash Flow | $112.8M | $107.6M+189.5% | $37.2M+124046.7% | -$30K+85.7% | -$210K-100.2% | $98.0M+32.5% | $74.0M+399.4% | $14.8M-6.8% | $15.9M-66.7% | $47.8M+86.4% | $25.6M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
LPTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | -2761.7% | -1902.6% | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | -2705.8% | -1834.3% | N/A | N/A | N/A | N/A |
| Return on Equity | 3.3%+197.3pp | -194.0%-59.3pp | -134.7%-41.9pp | -92.8%-55.1pp | -37.6%+21.4pp | -59.0% | N/A | -252.2%+15.2pp | -267.4% | N/A |
| Return on Assets | 3.1%+141.5pp | -138.4%-27.2pp | -111.2%-33.6pp | -77.6%-43.2pp | -34.4%+16.2pp | -50.6%+391.1pp | -441.7%-320.4pp | -121.3%-19.0pp | -102.3%+294.7pp | -397.0% |
| Current Ratio | 35.56+32.1x | 3.41-2.2x | 5.64-0.4x | 6.05-5.6x | 11.70+4.6x | 7.09+6.6x | 0.50-2.2x | 2.69-1.9x | 4.55+4.4x | 0.11 |
| Debt-to-Equity | 0.06-0.3x | 0.40+0.2x | 0.210.0x | 0.20+0.1x | 0.09-0.1x | 0.17 | N/A | 1.08-0.5x | 1.61 | N/A |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Leap Therapeutic Ranks
Frequently Asked Questions
Is Leap Therapeutic profitable?
Yes, Leap Therapeutic (LPTX) reported a net income of $5.0M in fiscal year 2025.
What is Leap Therapeutic's EBITDA?
Leap Therapeutic (LPTX) had EBITDA of -$41.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Leap Therapeutic's return on equity (ROE)?
Leap Therapeutic (LPTX) has a return on equity of 3.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Leap Therapeutic's operating cash flow?
Leap Therapeutic (LPTX) recorded an outflow of $43.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Leap Therapeutic's total assets?
Leap Therapeutic (LPTX) had $163.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Leap Therapeutic spend on research and development?
Leap Therapeutic (LPTX) invested $25.7M in research and development during fiscal year 2025.
What is Leap Therapeutic's current ratio?
Leap Therapeutic (LPTX) had a current ratio of 35.56 as of fiscal year 2025, which is generally considered healthy.
What is Leap Therapeutic's debt-to-equity ratio?
Leap Therapeutic (LPTX) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Leap Therapeutic's return on assets (ROA)?
Leap Therapeutic (LPTX) had a return on assets of 3.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Leap Therapeutic's cash runway?
Based on fiscal year 2025 data, Leap Therapeutic (LPTX) had $14.0M in cash against an annual operating cash burn of $43.9M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Leap Therapeutic's Piotroski F-Score?
Leap Therapeutic (LPTX) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Leap Therapeutic's earnings high quality?
For every $1 of reported earnings, Leap Therapeutic (LPTX) used $8.78 of operating cash (-$43.9M OCF vs $5.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Leap Therapeutic cover its interest payments?
Leap Therapeutic (LPTX) reported an operating loss of $41.1M against $24K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.